Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
eNq1mF1v2jAUhu/5FVHuSQgdA6ZAtbF2Q2o1Ros27aYyyQHMUjs9tvnor59D6EYnR20N5g7bec+Jz+vHR4nPN/eZtwIUlLOeHwUN3wOW8JSyec+f3F7WO/55vxYvyYocLGsHjSBq+l6SESF6fjEbTIEwEfy8vvoM+nlAv1/zYj5dQiKfrVOSZsFXIhbXJC/WePGK09S7B7ngac/PldyNerGQqLPorzn+FjlJIA73I4ezy7t3h+NxWIi9QlUJwCvC5kZRYFaaiUIEJgdEwpzjtiLfMyttKsYguMIERkQuRshXNIXUGGJGMgFWQWbr9AZwlYEsghjFw2VyL6zEyZJsxvAwNCf9Uc8O5EbWG/Wo3e40W61uU/9aVqHwYKvMVdAvESZ3UfMsanUbIbDwcSvpnFiWZsRRksxRUagYPPeVozgIDy8WP6Uiz8g2WIrcdqsIEj0NqE+/uxcp3uAWNY8yvWf/6TOVZeEbs57saeEo4wJGA66YrIDG5dh2IwacSdhUV9SOc3Kz9yIFcTrZR87MjB+paUYTW6Jp5igQcjIeVgPthCz4RARM0B0MflCW8rU4PWQOi+oo+3zHSaNojml01+x23ketlvUZ+qUdVHG/XCjkOYQaP1QcQ5Uhm/FjeaJNaZZ6suSp3LhrcnhCMqhoc+qWZNE2fOrKnBnd3SEqJ4yiXy5ubd3xXQFub3Z/jdI07f2tqx12XbBce7Ey8bc7uzzgThpghWZwLKTMxYcwXBBRF0TvUDDDUzP94BZ113k7uarL1qXkoqPUp+WF9/ri2B6wly7yY5vT/fP7JtgYQ6KCI+pQstgZMYcXp4fwv87UWdqjZ9BwF2bXRRJJOXPV3qipUfE47Ou6skvUcPg2m9GKryCVvozD8gtMvxaHxdeXfu0PA8DgBw==
KcKDgrhTTXyVHxHk
